期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 15, 期 5, 页码 563-573出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2017.0059
关键词
-
类别
资金
- Astellas
- AstraZeneca
- Celldex Therapeutics
- Clovis Oncology
- Genomic Health, Inc.
- Kyowa Hakko Kirin
- Jazz Pharmaceuticals
- Novartis Pharmaceuticals Corporation
- NOVOCURE
- Merck Co., Inc.
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据